Cancer

Our lead development candidate, CDX-110, is in a proprietary phase II development program that has already shown a >50% prognosis improvement for patients with newly diagnosed malignant glioblastoma, a particularly aggressive form of brain cancer. New product candidates utilizing APC Targeting Technology™ are in various stages of research and preclinical development. These products include CDX-1307 and CDX-1401, which incorporate different tumor antigens for therapeutic application in melanoma and other cancers.

• CDX-110 — Clinical Program for Malignant Glioblastoma
  Our lead clinical development program, CDX-110, is an immunotherapy that targets the tumor specific molecule called EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), a protein that has been well validated as a target for cancer therapy.
• CDX-1307 — Cancer Program Using APC Technology
  Our lead APC Targeting Technology™ product candidate, CDX-1307, is in development for the treatment of colorectal, pancreatic, bladder and breast cancers that express the beta chain of human chorionic gonadotropin, known as βhCG, an antigen often found in tumors of these types of cancer.
• CDX-1401 — Treatment of Multiple Tumors
  This program is generating an APC-targeted antigen combination product candidate based on antigens chosen from the proprietary tumor target antigens that we have licensed from the Ludwig Cancer Institute, which include NY-ESO-1, MAGE-3, Melan-A and other antigens that are expressed by several major human cancers, including breast, colon, lung and prostate.